The Enterprise Value as of December 2025 (TTM) for Neuren Pharmaceuticals Limited (NURPF) is 2.45B

According to Neuren Pharmaceuticals Limited’s latest financial reports and current stock price. The company's current Enterprise Value is 2.45B. This represents a change of 7.05% compared to the average of 2.29B of the last 4 quarters.

Neuren Pharmaceuticals Limited (NURPF) Historical Enterprise Value (quarterly & annually)

How has NURPF Enterprise Value performed in the past?

The mean historical Enterprise Value of Neuren Pharmaceuticals Limited over the last ten years is 703.78M. The current 2.45B Enterprise Value has changed 34.75% with respect to the historical average. Over the past ten years (40 quarters), NURPF's Enterprise Value was at its highest in in the December 2023 quarter at 3.14B. The Enterprise Value was at its lowest in in the June 2006 quarter at 0.

Neuren Pharmaceuticals Limited (NURPF) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Neuren Pharmaceuticals Limited Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Neuren Pharmaceuticals Limited (NURPF) Average Enterprise Value

How has NURPF Enterprise Value performed in the past?

The current Enterprise Value of Neuren Pharmaceuticals Limited (NURPF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Neuren Pharmaceuticals Limited (NURPF) Enterprise Value vs. Peers

How is NURPF’s Enterprise Value compared to its peers?

Neuren Pharmaceuticals Limited’s Enterprise Value is greater than Molecular Partners AG (46.65M), greater than MediciNova, Inc. (42.06M), greater than Anebulo Pharmaceuticals, Inc. (87.02M), greater than Champions Oncology, Inc. (79.51M), greater than Cyteir Therapeutics, Inc. (-37516738.00), greater than Aerovate Therapeutics, Inc. (355.20M), greater than Enliven Therapeutics, Inc. (1.15B), greater than MoonLake Immunotherapeutics (724.26M), greater than Structure Therapeutics Inc. (1.75B), greater than Compass Therapeutics, Inc. (719.89M), greater than Ventyx Biosciences, Inc. (548.92M), greater than Keros Therapeutics, Inc. (145.67M), less than Crinetics Pharmaceuticals, Inc. (4.44B), less than Cerevel Therapeutics Holdings, Inc. (7.68B), less than Vaxcyte, Inc. (5.83B), greater than Assembly Biosciences, Inc. (282.59M), greater than NextCure, Inc. (33.89M), less than Nuvation Bio Inc. (2.75B), greater than Graphite Bio, Inc. (742.15M), greater than Instil Bio, Inc. (69.60M), greater than PMV Pharmaceuticals, Inc. (25.00M), greater than Olema Pharmaceuticals, Inc. (1.86B), greater than Enochian Biosciences, Inc. (35.00M), less than Scholar Rock Holding Corporation (4.43B), greater than Passage Bio, Inc. (-3704906.00),

Build a custom stock screener for Neuren Pharmaceuticals Limited (NURPF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Neuren Pharmaceuticals Limited using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Neuren Pharmaceuticals Limited (NURPF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Neuren Pharmaceuticals Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.